Form 4: LAVA Therapeutics NV Director Acquires Options
SEC Form 4 Filing
Kapil Dhingra, a director of LAVA Therapeutics NV, acquired options to purchase 33,390 common shares at $0.93 per share on February 13, 2025.
Summary
- On February 13, 2025, Kapil Dhingra, a director of LAVA Therapeutics NV, acquired options to purchase 33,390 common shares.
- The exercise price of the options is $0.93 per share.
- The options vest on February 13, 2026, contingent upon the director's continued service with the company.
- The options expire on February 12, 2035.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing an insider transaction. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing reflects insider activity, which is a common occurrence in publicly traded companies. It provides transparency into the holdings and transactions of company insiders.
Stakeholder Impact
- The transaction provides transparency to shareholders regarding insider activity.
Key Dates
| Date | Description |
|---|---|
| 02/13/2025 | Date of transaction: Director acquired options to purchase common shares. |
| 02/13/2026 | Vesting date: 100% of the options will vest, contingent upon continued service. |
| 02/12/2035 | Expiration date: Options expire. |
| 02/18/2025 | Date of signature on the Form 4 filing. |
Keywords
LAVA Therapeutics NV, Director, Options, Common Shares, Beneficial Ownership, Form 4, Securities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.